Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 07 Apr 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary) ; Prednisolone; Prednisone
- Indications Bullous pemphigoid
- Focus Registrational; Therapeutic Use
- Acronyms LIBERTY-BP; LIBERTY-BP ADEPT
- Sponsors Regeneron Pharmaceuticals
- 21 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 14 Apr 2023 Planned End Date changed from 15 Sep 2023 to 7 Jan 2025.
- 14 Apr 2023 Planned primary completion date changed from 27 Feb 2023 to 16 Oct 2024.